Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
ACS Appl Mater Interfaces. 2024 Oct 30;16(43):58072-58099. doi: 10.1021/acsami.4c13607. Epub 2024 Oct 21.
Atherosclerosis-induced coronary artery disease is a major cause of cardiovascular mortality. Clinically, conservative treatment strategies for atherosclerosis still focus on lifestyle interventions and the use of lipid-lowering and anticoagulant medications. Despite achieving some therapeutic effects, these approaches are limited by low bioavailability, long intervention periods, and significant side effects. With the advancement of nanotechnology, nanomaterials have demonstrated extraordinary potential in the biomedical field. Their excellent biocompatibility, surface modifiability, and high targeting capability not only enable efficient diagnosis of plaque progression but also allow precise drug delivery within atherosclerotic plaques, significantly enhancing drug bioavailability and reducing systemic side effects. Here, we systematically review the current research progress of nanomaterials in the field of atherosclerosis to summarize not only the types of nanomaterials but also their applications in both the diagnosis and treatment of atherosclerosis. Notably, in the context of plaque therapy, we provide a comprehensive overview of current nanomaterial applications based on their targeted therapeutic systems for different cell types within plaques. Additionally, we address the persistent challenge of clinical translation of nanomaterials by summarizing current issues and providing directions for innovation and improvement in nanomaterial design. Overall, we believe that this review systematically summarizes the applications and challenges of biomedical nanomaterials in atherosclerosis diagnosis and therapy, thereby offering insights and references for the development of therapeutic materials for atherosclerosis.
动脉粥样硬化性冠状动脉疾病是心血管疾病死亡率的主要原因。临床上,动脉粥样硬化的保守治疗策略仍然集中在生活方式干预和使用降脂和抗凝药物上。尽管这些方法取得了一些治疗效果,但它们受到生物利用度低、干预期长和严重副作用等限制。随着纳米技术的发展,纳米材料在生物医学领域表现出了非凡的潜力。它们卓越的生物相容性、表面可修饰性和高靶向能力不仅能够有效地诊断斑块的进展,还能够在动脉粥样硬化斑块内精确地输送药物,显著提高药物的生物利用度并减少全身副作用。在这里,我们系统地回顾了纳米材料在动脉粥样硬化领域的研究进展,不仅总结了纳米材料的类型,还总结了它们在动脉粥样硬化的诊断和治疗中的应用。值得注意的是,在斑块治疗方面,我们根据不同斑块内细胞类型的靶向治疗系统,全面概述了当前纳米材料的应用。此外,我们还通过总结当前存在的问题,并为纳米材料设计的创新和改进提供方向,来解决纳米材料临床转化的持久挑战。总的来说,我们相信,这篇综述系统地总结了生物医学纳米材料在动脉粥样硬化诊断和治疗中的应用和挑战,为动脉粥样硬化治疗材料的开发提供了思路和参考。